<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473953</url>
  </required_header>
  <id_info>
    <org_study_id>NN9223-3928</org_study_id>
    <secondary_id>U1111-1123-0547</secondary_id>
    <nct_id>NCT01473953</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects</brief_title>
  <official_title>Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America (USA). The aim of this trial is to
      investigate the safety, tolerability and pharmacokinetics (exposure in the body) of
      liraglutide-depot in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 0 and up to 21 days after treatment</time_frame>
    <description>TEAEs: AEs from 1st exposure (exp) until follow-up (FU) or AEs with onset before 1st exp increasing in severity up to the FU. Mild AEs: no or transient symptoms, no interference (inf) with subject's daily activities. Moderate AEs: marked symptoms, moderate inf with subject's daily activities. Severe AEs: considerable inf with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in death/ a life-threatening experience/ in-subject hospitalization/prolongation of existing hospitalisation; or persistent/significant disability/incapacity/congenital anomaly/birth defect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of Liraglutide After a Single Dose of Liraglutide-depot</measure>
    <time_frame>Day 0 through day 21 at 1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168, 336, 504 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration of Liraglutide After a Single Dose of Liraglutide-depot</measure>
    <time_frame>Day 0 through day 21 at 1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168, 336, 504 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve in the Period From the Time of Liraglutide-depot Administration to Infinity</measure>
    <time_frame>Day 0 through day 21 at 1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168, 336, 504 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Liraglutide Plasma Concentration Curve in the First Week Following Liraglutide-depot Administration for Subjects Without Liraglutide 6 mg/ml Pre-treatment</measure>
    <time_frame>1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve in the First Week Following Liraglutide-depot Administration for Subjects With Liraglutide 6 mg/ml Pre-treatment</measure>
    <time_frame>0 to 168 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibodies (Positive) or Without Antibodies (Negative) Against Liraglutide Observed at Pre-dose and at Last Follow-up</measure>
    <time_frame>Day 0 and Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1a: Lira-depot 2.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a: Lira-depot 6.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a: Lira-depot 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4a: Lira-depot 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide-depot</intervention_name>
    <description>Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.</description>
    <arm_group_label>Cohort 1a: Lira-depot 2.25 mg</arm_group_label>
    <arm_group_label>Cohort 2a: Lira-depot 6.75 mg</arm_group_label>
    <arm_group_label>Cohort 3a: Lira-depot 15 mg</arm_group_label>
    <arm_group_label>Cohort 4a: Lira-depot 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 20 and 35 kg/m^2 (both inclusive) with a body weight of
             at least 60 kg

          -  Apart from being obese (BMI above 30 kg/m^2) the subject has to be considered
             generally healthy

        Exclusion Criteria:

          -  Medical history of, or presence of, cancer, diabetes or any clinically significant
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine,
             haematological, dermatological, venereal, neurological, psychiatric diseases or other
             major disorders

          -  Clinical or laboratory findings which suggest that the subject cannot be considered
             generally healthy

          -  Prescription medicine and non-prescription medicine with few exceptions

          -  Current and prior history of alcohol or drug abuse

          -  Current smoking of more than 5 cigarettes per day

          -  Mental incapacity, language barriers, or unwillingness to comply with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <results_first_submitted>June 20, 2013</results_first_submitted>
  <results_first_submitted_qc>June 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2013</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at one site in Evansville, Indiana, USA.</recruitment_details>
      <pre_assignment_details>It was a Novo Nordisk business decision, and not a decision due to safety concerns, not to continue the development of liraglutide depot. Therefore cohorts with liraglutide pre-treatment were not initiated based on review of pharmacokinetic data, and hence no analysis was done. So no subjects were enrolled for the outcome measure 6.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1a: Lira-depot 2.25 mg</title>
          <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2a: Lira-depot 6.75 mg</title>
          <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3a: Lira-depot 15 mg</title>
          <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4a: Lira-depot 30 mg</title>
          <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1a: Lira-depot 2.25 mg</title>
          <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2a: Lira-depot 6.75 mg</title>
          <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3a: Lira-depot 15 mg</title>
          <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4a: Lira-depot 30 mg</title>
          <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="11.4"/>
                    <measurement group_id="B2" value="30.0" spread="12.6"/>
                    <measurement group_id="B3" value="29.8" spread="7.7"/>
                    <measurement group_id="B4" value="39.0" spread="8.4"/>
                    <measurement group_id="B5" value="28.5" spread="7.9"/>
                    <measurement group_id="B6" value="32.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Emergent Adverse Events (TEAEs)</title>
        <description>TEAEs: AEs from 1st exposure (exp) until follow-up (FU) or AEs with onset before 1st exp increasing in severity up to the FU. Mild AEs: no or transient symptoms, no interference (inf) with subject's daily activities. Moderate AEs: marked symptoms, moderate inf with subject's daily activities. Severe AEs: considerable inf with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in death/ a life-threatening experience/ in-subject hospitalization/prolongation of existing hospitalisation; or persistent/significant disability/incapacity/congenital anomaly/birth defect.</description>
        <time_frame>Day 0 and up to 21 days after treatment</time_frame>
        <population>The safety analysis set includes all subjects who were exposed to at least one dose of trial product. Subjects in the safety analysis set contribute to the evaluation ‘as treated’.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: Lira-depot 2.25 mg</title>
            <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2a: Lira-depot 6.75 mg</title>
            <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Lira-depot 15 mg</title>
            <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4a: Lira-depot 30 mg</title>
            <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Adverse Events (TEAEs)</title>
          <description>TEAEs: AEs from 1st exposure (exp) until follow-up (FU) or AEs with onset before 1st exp increasing in severity up to the FU. Mild AEs: no or transient symptoms, no interference (inf) with subject's daily activities. Moderate AEs: marked symptoms, moderate inf with subject's daily activities. Severe AEs: considerable inf with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in death/ a life-threatening experience/ in-subject hospitalization/prolongation of existing hospitalisation; or persistent/significant disability/incapacity/congenital anomaly/birth defect.</description>
          <population>The safety analysis set includes all subjects who were exposed to at least one dose of trial product. Subjects in the safety analysis set contribute to the evaluation ‘as treated’.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total adverse events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration of Liraglutide After a Single Dose of Liraglutide-depot</title>
        <time_frame>Day 0 through day 21 at 1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168, 336, 504 hours post dose</time_frame>
        <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. This evaluation was not done on placebo cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: Lira-depot 2.25 mg</title>
            <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2a: Lira-depot 6.75 mg</title>
            <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Lira-depot 15 mg</title>
            <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4a: Lira-depot 30 mg</title>
            <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration of Liraglutide After a Single Dose of Liraglutide-depot</title>
          <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. This evaluation was not done on placebo cohort.</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="690" spread="52" lower_limit="52"/>
                    <measurement group_id="O2" value="2141" spread="25" lower_limit="25"/>
                    <measurement group_id="O3" value="6977" spread="62" lower_limit="62"/>
                    <measurement group_id="O4" value="40041" spread="35" lower_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration of Liraglutide After a Single Dose of Liraglutide-depot</title>
        <time_frame>Day 0 through day 21 at 1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168, 336, 504 hours post dose</time_frame>
        <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. This evaluation was not done on placebo cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: Lira-depot 2.25 mg</title>
            <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2a: Lira-depot 6.75 mg</title>
            <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Lira-depot 15 mg</title>
            <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4a: Lira-depot 30 mg</title>
            <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration of Liraglutide After a Single Dose of Liraglutide-depot</title>
          <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. This evaluation was not done on placebo cohort.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.13" spread="92.28" lower_limit="92.28"/>
                    <measurement group_id="O2" value="8.09" spread="55.78" lower_limit="55.78"/>
                    <measurement group_id="O3" value="13.74" spread="22.13" lower_limit="22.13"/>
                    <measurement group_id="O4" value="10.46" spread="24.62" lower_limit="24.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Curve in the Period From the Time of Liraglutide-depot Administration to Infinity</title>
        <time_frame>Day 0 through day 21 at 1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168, 336, 504 hours post dose</time_frame>
        <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. 1 subject was not included for this evaluation in the cohort 1a arm due to insufficient data. This evaluation was not done on placebo cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: Lira-depot 2.25 mg</title>
            <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2a: Lira-depot 6.75 mg</title>
            <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Lira-depot 15 mg</title>
            <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4a: Lira-depot 30 mg</title>
            <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve in the Period From the Time of Liraglutide-depot Administration to Infinity</title>
          <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. 1 subject was not included for this evaluation in the cohort 1a arm due to insufficient data. This evaluation was not done on placebo cohort.</population>
          <units>pmol.h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43840" spread="24" lower_limit="24"/>
                    <measurement group_id="O2" value="116935" spread="20" lower_limit="20"/>
                    <measurement group_id="O3" value="360000" spread="46" lower_limit="46"/>
                    <measurement group_id="O4" value="1443038" spread="22" lower_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Liraglutide Plasma Concentration Curve in the First Week Following Liraglutide-depot Administration for Subjects Without Liraglutide 6 mg/ml Pre-treatment</title>
        <time_frame>1,3,6,12,18, 24, 36, 48, 72, 96, 120, 168 hours post dose</time_frame>
        <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. 1 subject was not included for this evaluation in the cohort 1a arm due to insufficient data. Cohorts with liraglutide pre-treatment were not initiated based on review of pharmacokinetic data, and hence no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: Lira-depot 2.25 mg</title>
            <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2a: Lira-depot 6.75 mg</title>
            <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Lira-depot 15 mg</title>
            <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4a: Lira-depot 30 mg</title>
            <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Liraglutide Plasma Concentration Curve in the First Week Following Liraglutide-depot Administration for Subjects Without Liraglutide 6 mg/ml Pre-treatment</title>
          <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. 1 subject was not included for this evaluation in the cohort 1a arm due to insufficient data. Cohorts with liraglutide pre-treatment were not initiated based on review of pharmacokinetic data, and hence no analysis was done.</population>
          <units>pmol.h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37298" spread="27" lower_limit="27"/>
                    <measurement group_id="O2" value="114101" spread="20" lower_limit="20"/>
                    <measurement group_id="O3" value="316642" spread="46" lower_limit="46"/>
                    <measurement group_id="O4" value="1363187" spread="21" lower_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Curve in the First Week Following Liraglutide-depot Administration for Subjects With Liraglutide 6 mg/ml Pre-treatment</title>
        <time_frame>0 to 168 hours after dosing</time_frame>
        <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. Cohorts with liraglutide pre-treatment were not initiated based on review of pharmacokinetic data, and hence no analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: Lira-depot 2.25 mg</title>
            <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2a: Lira-depot 6.75 mg</title>
            <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Lira-depot 15 mg</title>
            <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4a: Lira-depot 30 mg</title>
            <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve in the First Week Following Liraglutide-depot Administration for Subjects With Liraglutide 6 mg/ml Pre-treatment</title>
          <population>Full analysis set consisted of all subjects who were randomised and exposed to randomised treatment. Cohorts with liraglutide pre-treatment were not initiated based on review of pharmacokinetic data, and hence no analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibodies (Positive) or Without Antibodies (Negative) Against Liraglutide Observed at Pre-dose and at Last Follow-up</title>
        <time_frame>Day 0 and Day 21</time_frame>
        <population>The safety analysis set includes all subjects who were exposed to at least one dose of trial product. Subjects in the safety analysis set contribute to the evaluation ‘as treated’.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: Lira-depot 2.25 mg</title>
            <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2a: Lira-depot 6.75 mg</title>
            <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3a: Lira-depot 15 mg</title>
            <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4a: Lira-depot 30 mg</title>
            <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibodies (Positive) or Without Antibodies (Negative) Against Liraglutide Observed at Pre-dose and at Last Follow-up</title>
          <population>The safety analysis set includes all subjects who were exposed to at least one dose of trial product. Subjects in the safety analysis set contribute to the evaluation ‘as treated’.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected in a timeframe of 7 days + 14 days follow up (Day 0 and up to 21 days after treatment)</time_frame>
      <desc>The safety analysis set includes all subjects who were exposed to at least one dose of trial product. Subjects in the safety analysis set contribute to the evaluation ‘as treated’.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1a: Lira-depot 2.25 mg</title>
          <description>In cohort 1a a single subcutaneous dose of 2.25 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2a: Lira-depot 6.75 mg</title>
          <description>In cohort 2a a single subcutaneous dose of 6.75 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3a: Lira-depot 15 mg</title>
          <description>In cohort 3a a single subcutaneous dose of 15 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4a: Lira-depot 30 mg</title>
          <description>In cohort 4a a single subcutaneous dose of 30 mg liraglutide-depot was administered.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>In the placebo group a corresponding volume of liraglutide-depot placebo was administered subcutaneous (s.c.).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

